HUS2100011I1 - Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére - Google Patents

Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére

Info

Publication number
HUS2100011I1
HUS2100011I1 HUS2100011C HUS2100011C HUS2100011I1 HU S2100011 I1 HUS2100011 I1 HU S2100011I1 HU S2100011 C HUS2100011 C HU S2100011C HU S2100011 C HUS2100011 C HU S2100011C HU S2100011 I1 HUS2100011 I1 HU S2100011I1
Authority
HU
Hungary
Prior art keywords
methods
same
inflammatory diseases
treat inflammatory
selectin antibodies
Prior art date
Application number
HUS2100011C
Other languages
English (en)
Original Assignee
Novartis Pharma Ag
Oklahoma Med Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Ag, Oklahoma Med Res Found filed Critical Novartis Pharma Ag
Publication of HUS2100011I1 publication Critical patent/HUS2100011I1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUS2100011C 2006-12-01 2021-04-07 Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére HUS2100011I1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87217006P 2006-12-01 2006-12-01
EP13164403.1A EP2662091B1 (en) 2006-12-01 2007-11-30 Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases

Publications (1)

Publication Number Publication Date
HUS2100011I1 true HUS2100011I1 (hu) 2021-05-28

Family

ID=39492818

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE13164403A HUE041957T2 (hu) 2006-12-01 2007-11-30 Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
HUS2100011C HUS2100011I1 (hu) 2006-12-01 2021-04-07 Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
HUS2100015C HUS2100015I1 (hu) 2006-12-01 2021-04-23 Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE13164403A HUE041957T2 (hu) 2006-12-01 2007-11-30 Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS2100015C HUS2100015I1 (hu) 2006-12-01 2021-04-23 Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére

Country Status (11)

Country Link
US (2) US8377440B2 (hu)
EP (3) EP2097105A4 (hu)
CY (2) CY1121072T1 (hu)
DK (1) DK2662091T3 (hu)
ES (1) ES2699273T3 (hu)
HU (3) HUE041957T2 (hu)
LT (2) LT2662091T (hu)
PL (1) PL2662091T3 (hu)
PT (1) PT2662091T (hu)
SI (1) SI2662091T1 (hu)
WO (1) WO2008069999A2 (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2662091T (lt) 2006-12-01 2018-12-10 Novartis Ag Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui
US20110212096A1 (en) * 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
EP2654781B1 (en) * 2010-12-21 2018-01-24 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification
US10206941B2 (en) 2013-07-09 2019-02-19 President And Fellows Of Harvard College Venule endothelial cell genes and uses thereof
WO2015006501A2 (en) 2013-07-09 2015-01-15 President And Fellows Of Harvard College Microvessel endothelial cell surface markers and uses thereof
JOP20190101A1 (ar) * 2016-11-03 2019-05-05 Novartis Ag أنظمة علاج
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
WO2018167119A1 (en) 2017-03-15 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for the treatment of thrombosis in patients suffering from a myeloproliferative neoplasm
CA3063051A1 (en) * 2017-05-10 2018-11-15 The Wistar Institute Of Anatomy And Biology Optimized nucleic acid antibody constructs
EP3642631B1 (en) 2017-06-20 2022-03-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for identifying whether patients with acute decompensated heart failure (adhf) exhibit a hypercoagulable state
CN107299112A (zh) * 2017-06-22 2017-10-27 广东药科大学 一种炎症分子（psgl‑1）缺失的脂代谢异常模型的构建及其应用
WO2019025847A1 (en) 2017-08-04 2019-02-07 Novartis Ag TREATMENT DIAGRAMS
US20210002374A1 (en) 2018-03-08 2021-01-07 Novartis Ag USE OF an anti-P-selectin antibody
WO2020247698A1 (en) 2019-06-07 2020-12-10 Novartis Ag Use of an anti-p-selectin antibody
EP3790545A4 (en) 2019-07-17 2021-07-28 Emmaus Medical, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF SICKLE CLEANEMIA AND THALASSEMIA
AU2020373017B2 (en) 2019-10-30 2024-06-06 Novartis Ag Crizanlizumab containing antibody formulation
EP4073115A1 (en) 2019-12-09 2022-10-19 Novartis AG Anti-interleukin 1 beta antibodies for treatment of sickle cell disease
US20230279394A1 (en) 2019-12-18 2023-09-07 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
WO2022269518A2 (en) 2021-06-23 2022-12-29 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4783399A (en) 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US6309639B1 (en) * 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU678757B2 (en) 1991-09-30 1997-06-12 Biogen, Inc. Inhibition of vascular narrowing using anti-padgem antibodies
PT639224E (pt) 1992-04-30 2000-12-29 Genentech Inc Variantes do dominio de lectina da selectina
US6033667A (en) 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
ES2197150T3 (es) * 1992-05-05 2004-01-01 Aeres Biomedical Limited Anticuerpos contra p-selectina y sus utilizaciones.
EP0804235A4 (en) 1993-05-04 2001-09-19 Aeres Biomedical Ltd ANTIBODIES AGAINST SELECTIN P AND USES THEREOF
US5914110A (en) 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
DE69534761T2 (de) * 1994-06-03 2006-10-12 The CBR Institute for Biomedical Reserach, Inc., Boston Zusammensetzungen zur behandlung und vorbeugung von atherosklerose
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
GB9612629D0 (en) 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US6677436B1 (en) 1998-04-03 2004-01-13 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
US7067313B1 (en) 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
AU2001261735B2 (en) 2000-05-19 2006-09-21 The Center For Blood Research, Inc. Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US20030198639A1 (en) 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040072796A1 (en) * 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients
ES2633311T3 (es) * 2002-12-16 2017-09-20 Genentech, Inc. Variantes de inmunoglobulina y usos de las mismas
PT1737891E (pt) * 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
US20110212096A1 (en) * 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
LT2662091T (lt) * 2006-12-01 2018-12-10 Novartis Ag Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui
WO2009140623A2 (en) 2008-05-15 2009-11-19 Selexys Pharmaceuticals Corporation Anti-psgl-1 antibodies and methods of identification and use
EP2654781B1 (en) 2010-12-21 2018-01-24 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification

Also Published As

Publication number Publication date
EP2662091A2 (en) 2013-11-13
WO2008069999A3 (en) 2008-12-04
CY2021009I1 (el) 2021-10-15
EP2097105A4 (en) 2010-09-15
ES2699273T3 (es) 2019-02-08
WO2008069999A2 (en) 2008-06-12
US20140072551A1 (en) 2014-03-13
US9556266B2 (en) 2017-01-31
SI2662091T1 (sl) 2019-01-31
PL2662091T3 (pl) 2019-05-31
US8377440B2 (en) 2013-02-19
PT2662091T (pt) 2018-12-03
LTPA2021506I1 (lt) 2021-05-10
EP2662091B1 (en) 2018-08-22
EP2662091A3 (en) 2014-03-12
CY2021009I2 (el) 2021-12-31
EP3501538A1 (en) 2019-06-26
DK2662091T3 (en) 2018-12-17
US20110243926A1 (en) 2011-10-06
EP2097105A2 (en) 2009-09-09
HUE041957T2 (hu) 2019-06-28
LTC2662091I2 (lt) 2022-10-10
CY1121072T1 (el) 2019-12-11
HUS2100015I1 (hu) 2021-05-28
LT2662091T (lt) 2018-12-10

Similar Documents

Publication Publication Date Title
HUS2100015I1 (hu) Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
IL248723B (en) Specific antibodies against the bcr complex and methods of using them
HK1223114A1 (zh) 抗因子 單克隆抗體及其使用方法
IL198729A0 (en) Human monoclonal antibodies to btla and methods of use
HK1141811A1 (en) Human antibodies to human cd20 and method of using thereof cd20
EP2086583A4 (en) FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USE
EP2212432A4 (en) COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES
EP2315780B8 (en) Compositions and methods of use for therapeutic antibodies
PT2185719E (pt) Anticorpos anti-rantes e processos para a sua utilização
IL196920A0 (en) Compositions and methods using anti-csi antibodies to treat multiple myeloma
EP2195025A4 (en) THERAPEUTIC ANTIBODY PURIFICATION METHOD AND METHOD OF USE
IL232011A0 (en) Antibodies to 7egfl and methods of using them
SI2068930T1 (sl) Sestavki in postopki, pri katerih se uporabljajo anti-CS1 protitelesa za zdravljenje multiplega mieloma
ZA200807225B (en) Antibodies to EGFL7 and methods for their use
IL202502A0 (en) Agents for the treatment of inflammatory diseases and methods of using same